The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome.

Dodson WC, Hughes CL, Whitesides DB, Haney AF

The Journal of clinical endocrinology and metabolism1 Jul 1987Cited by 47 (Europe PMC)

PMID2953752DOI10.1210/jcem-65-1-95PepBankPUB-02953752

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with PCO, leuprolide before and during hMG treatment prevented preovulatory LH rises compared with hMG alone.
In plain wordsIn women with PCO, adding leuprolide prevented preovulatory LH rises compared with hMG alone.
Peptide
Leuprolide
Outcome
DecreasePreovulatory LH rise
Study
n: not reported in source
Comparator
hMG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
dailyAs given in this study (human).
Source sentences
Summary
Compared to ovulation induction using hMG alone, leuprolide administration before and during hMG treatment prevented preovulatory rises in serum LH and P concentrations, while having no effect on serum FSH, testosterone, estradiol, and dehydroepiandrosterone sulfate.
3 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the effect of leuprolide acetate, a long-acting GnRH agonist, on serum gonadotropin and sex steroid concentrations before and during human menopausal gonadotropin (hMG) induction of ovulation in women with PCO.
Summary · context
In this controlled prospective randomized study, leuprolide was administered daily for 4 weeks, followed by concomitant hMG administration.
Summary · context
Gonadotropin and steroid hormone concentrations were compared with those during ovulation induction cycles in women with PCO receiving hMG only.
Report a problemFND-0295375203
02HumanRandomized controlled trialEfficacy outcome
In women with PCO, leuprolide before and during hMG treatment prevented preovulatory progesterone rises compared with hMG alone.
In plain wordsIn women with PCO, adding leuprolide prevented preovulatory progesterone rises compared with hMG alone.
Peptide
Leuprolide
Outcome
DecreasePreovulatory progesterone rise
Study
n: not reported in source
Comparator
hMG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
dailyAs given in this study (human).
Source sentences
Summary
Compared to ovulation induction using hMG alone, leuprolide administration before and during hMG treatment prevented preovulatory rises in serum LH and P concentrations, while having no effect on serum FSH, testosterone, estradiol, and dehydroepiandrosterone sulfate.
3 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the effect of leuprolide acetate, a long-acting GnRH agonist, on serum gonadotropin and sex steroid concentrations before and during human menopausal gonadotropin (hMG) induction of ovulation in women with PCO.
Summary · context
In this controlled prospective randomized study, leuprolide was administered daily for 4 weeks, followed by concomitant hMG administration.
Summary · context
Gonadotropin and steroid hormone concentrations were compared with those during ovulation induction cycles in women with PCO receiving hMG only.
Report a problemFND-0295375204
03HumanRandomized controlled trialEfficacy outcome
In women with PCO, added leuprolide did not affect serum FSH, testosterone, estradiol or dehydroepiandrosterone sulfate versus hMG alone.
In plain wordsIn women with PCO, added leuprolide did not affect blood FSH, testosterone, estradiol or dehydroepiandrosterone sulfate compared with hMG alone.
Peptide
Leuprolide
Outcome
No significant changeFSH, testosterone, estradiol and DHEAS during induction
Study
n: not reported in source
Comparator
hMG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
dailyAs given in this study (human).
Source sentences
Summary
Compared to ovulation induction using hMG alone, leuprolide administration before and during hMG treatment prevented preovulatory rises in serum LH and P concentrations, while having no effect on serum FSH, testosterone, estradiol, and dehydroepiandrosterone sulfate.
3 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the effect of leuprolide acetate, a long-acting GnRH agonist, on serum gonadotropin and sex steroid concentrations before and during human menopausal gonadotropin (hMG) induction of ovulation in women with PCO.
Summary · context
In this controlled prospective randomized study, leuprolide was administered daily for 4 weeks, followed by concomitant hMG administration.
Summary · context
Gonadotropin and steroid hormone concentrations were compared with those during ovulation induction cycles in women with PCO receiving hMG only.
Report a problemFND-0295375205
04HumanNon-randomized trialEfficacy outcome
In women with PCO, daily leuprolide for 4 weeks significantly decreased serum LH, estradiol and testosterone.
In plain wordsIn women with PCO, daily leuprolide for 4 weeks significantly reduced blood LH, estradiol and testosterone.
Peptide
Leuprolide
Outcome
DecreaseLH, estradiol and testosterone after pretreatment
Study
n: not reported in source
Comparator
Before leuprolide pretreatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
daily · 4 weeksAs given in this study (human).
Source sentences
Summary
Daily administration of leuprolide for 4 weeks resulted in significantly decreased serum LH, estradiol, and testosterone concentrations, but no change in serum progesterone, FSH, and dehydroepiandrosterone sulfate.
3 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the effect of leuprolide acetate, a long-acting GnRH agonist, on serum gonadotropin and sex steroid concentrations before and during human menopausal gonadotropin (hMG) induction of ovulation in women with PCO.
Summary · context
In this controlled prospective randomized study, leuprolide was administered daily for 4 weeks, followed by concomitant hMG administration.
Summary · context
Gonadotropin and steroid hormone concentrations were compared with those during ovulation induction cycles in women with PCO receiving hMG only.
Report a problemFND-0295375201
05HumanNon-randomized trialEfficacy outcome
In women with PCO, daily leuprolide for 4 weeks did not change serum progesterone, FSH or dehydroepiandrosterone sulfate.
In plain wordsIn women with PCO, daily leuprolide for 4 weeks did not change blood progesterone, FSH or dehydroepiandrosterone sulfate.
Peptide
Leuprolide
Outcome
No significant changeProgesterone, FSH and DHEAS after pretreatment
Study
n: not reported in source
Comparator
Before leuprolide pretreatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
daily · 4 weeksAs given in this study (human).
Source sentences
Summary
Daily administration of leuprolide for 4 weeks resulted in significantly decreased serum LH, estradiol, and testosterone concentrations, but no change in serum progesterone, FSH, and dehydroepiandrosterone sulfate.
3 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the effect of leuprolide acetate, a long-acting GnRH agonist, on serum gonadotropin and sex steroid concentrations before and during human menopausal gonadotropin (hMG) induction of ovulation in women with PCO.
Summary · context
In this controlled prospective randomized study, leuprolide was administered daily for 4 weeks, followed by concomitant hMG administration.
Summary · context
Gonadotropin and steroid hormone concentrations were compared with those during ovulation induction cycles in women with PCO receiving hMG only.
Report a problemFND-0295375202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.